Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Year 5 > OPB > Flashcards

OPB Flashcards

1
Q

Incidence of breast cancer

A

1 in 8 women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most common cancer in women

A

Breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

2 most common cancers overall

A

1) Lung

2) Breast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Risk factors for breast cancer

A
  • Age >50
  • Benign breast disease
  • Proliferative types of hyperplasia
  • Exposure to ionising radiation
  • Later first child birth
  • History of breast cancer
  • Family history of breast or ovarian cancer in a 1st degree relative
  • Hormone therapy use
  • Nulliparity
  • Obesity
  • Alcohol
  • No breast-feeding
  • Elevated endogenous oestrogen levels
  • Hormonal contraceptive use
  • Increased mammography density of breast tissue
  • Menarche <12
  • Menopause >45
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Features which may make you suspect inflammatory breast cancer

A
  • Erythema
  • Oedema
  • Peau d’orange
  • Nipple retraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinical features of breast cancer

A
  • Breast lump
  • Change in shape of breast
  • Nipple discharge
  • Skin changes
  • Pain
  • Ulceration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Most common sites of metastasis for breast cancer

A
  • Bone
  • Lung
  • Liver
  • Pleura
  • Adrenal glands
  • Skin
  • Brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Investigations to consider in a patient with ?breast cancer

A
  • Mammogram (>40 years old)
  • US (<40 years old)
  • MRI
  • FNA/core biopsy/vacuum assisted biopsy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Factors influencing choice of surgical management option in breast cancer patients

A
  • Patient age
  • Comorbidities
  • Patient preference
  • Tumour stage (size, lymphovascular invasion, nodal involvement, location)
  • Tumour biomarkers
  • Tumour: breast size ratio
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Contra-indications for breast conservation surgery/wide local incision/lumpectomy in breast cancer patients?

A
  • Large primary tumour
  • Central primary tumour
  • Small breast size
  • Patient unfit for surgery/follow up radiotherapy
  • Severe lung/heart disease
  • Pes excavatum
  • Chronic lack of mobility at ipsilateral shoulder
  • Kyphoscoliosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Indications for mastectomy (rather than WLE) in breast cancer patients

A
  • Multifocal disease
  • Bilateral disease where it is not possible to conserve the breasts
  • Extensive DCIS
  • Patients unsuitable for breast radiotherapy
  • Significant family history of risk regarding procedures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Indications for axillary sampling (rather than axillary clearance)

A
  • Negative findings on US of the axilla +/- biopsy

- High upper quadrant tumour (avoid irradiation of ‘cleared’ axilla)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indications for axillary clearance (rather than axillary sampling)

A
  • Histologically confirmed invasive breast cancer/ >1 node axilla biopsy confirmed malignant
  • Patient preference
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Main complication of axillary clearance

A

Lymphoedema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aim of adjuvant therapy in breast cancer patients

A

Aim to reduce risk of recurrence locally or systemically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Indications for breast adjuvant radiotherapy in breast cancer patients

A
  • No lymph node metastases in an adequate axillary node sample (4 nodes)
  • <4 nodes involved in an adequate axillary node clearance (10 nodes)
  • Invasive disease with inadequate excision margins unsuitable for re-excision
  • Conserved breast unsuitable for excision
  • T4 disease at presentation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Indications for chest wall radiotherapy after mastectomy in breast cancer patients

A
  • Tumour size >5cm
  • 4 or more involved nodes
  • Involved resection margins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Indications for adjuvant chemotherapy after surgery in breast cancer patients

A
  • High-risk early breast cancer
  • Grade 3
  • LVI
  • Nodal involvement
  • Triple negative
  • HER2+
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Main hormonal treatment of breast cancer in pre-menopausal women

A
  • 5 years Tamoxifen

OR

  • 5 years tamoxifen + another 5 years (if still pre-menopausal) or 5 years of letrozole (if post-menopausal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Main hormonal treatments of breast cancer in post-menopausal women

A
  • 5 years tamoxifen

OR

  • 5 years tamoxifen + 5 years letrozole

OR

  • 5 years letrozole
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Indications for 5 years of tamoxifen treatment in pre-menopausal women with breast cancer

A
  • Grade 1-2
  • T1 <2cm
  • Node -
  • ER+
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Indications for 10 years of tamoxifen or 5 years or tamoxifen + 5 years letrozole in pre-menopausal women with breast cancer

A
  • T2-4
  • Grade 3
  • Node +
  • HER2+
  • ER poor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Indications for 5 years of treatment with tamoxifen in post-menopausal women with breast cancer

A
  • Grade 1-2
  • T1 <2cm
  • Node -
  • ER+
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Indications for 5 years of treatment with tamoxifen + 5 years with letrozole in post-menopausal women with breast cancer

A
  • Grade 2
  • T2 >2cm
  • Node -
  • ER+
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Indications for 5 years of treatment with letrozole in post-menopausal women with breast cancer

A
  • Grade 3
  • T3-4
  • Node +
  • HER2+
  • ER poor
  • Response to neo-adjuvant aromatase inhibitors
  • Tamoxifen contra-indicated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What scan needs to be done before starting a breast cancer patient on letrozole

A

DEXA scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How would you check menopausal status in patients on tamoxifen?

A

Check hormone levels after 6 weeks off tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

How would you confirm menopause in a women <50 on tamoxifen?

A
  • FSH >30 on 2 occasions >6 weeks apart
    AND
  • Amenorrhoeic for 24 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

How would you confirm menopause in a women 50-54 on tamoxifen?

A
  • FSH >30 on 2 occasions >6 weeks apart
    AND
  • Amenorrhoeic for 12 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Which group of breast cancer patients should be offered immunotherapy, and what treatment would you offer?

A
  • HER2 + patients

- Herceptin for 6-12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Features that increase risk of breast cancer recurrence

A
  • Tumour size >1cm
  • ER-
  • Involvement of lymph nodes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Long-term follow up of ‘cured’ breast cancer patients

A

YEAR 1

  • Clinical examination and mammogram
  • Check family history and consider genetic testing

YEAR 2-4

  • Mammogram
  • Clinical examination if bilateral mastectomy performed

YEAR 5

  • Clinical examination and mammogram
  • Consider changing endocrine therapy

YEAR 6-10
- Mammogram

Year 10

  • Mammogram with clinical examination
  • Stop endocrine therapy as appropriate
  • Discharge to breast screening programme
  • Contact genetics if high risk patient
  • Reassess family history and consider genetic referral
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Define neutropenic sepsis

A

WCC <1 + pyrexia as a potential complication of systemic anti-cancer treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

When are patients on SACT at risk of neutropenic sepsis?

A

Days 7-21 post-treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Risk factors for neutropenic sepsis

A
  • Age >65
  • Poor performance status
  • Previous neutropenic sepsis
  • Combined chemotherapy + radiotherapy
  • Poor nutrition
  • Advanced disease
  • Co-morbidities
  • Active infection
  • Central venous catheters
  • Surgical wounds
  • Previous MRSA colonisation
  • Unwell contacts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Clinical features of neutropenic sepsis

A
  • Pyrexia (temp >37.5 or <36)
  • Malaise
  • Infective symptoms e.g. cough
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What scoring assessment is used for initial assessment of patients with ?neutropenic sepsis

A

Formal risk assessment - combines NEWS score and MASCC score (maximum score is 26 - patients <21 or with NEWS Score >6 are high risk)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What investigations would you carry out in a patient with ?neutropenic sepsis?

A
  • Clinical examination (including mouth and perineum) for signs of infection
  • Daily bloods (CRP, FBC, U&Es, LFTs) while on antibiotics - must be requested URGENTLY on admission and following day
  • Peripheral (and central) blood cultures
  • Viral throat swabs
  • Urine dipstick and MSU
  • CXR
  • Consider abdominal x-ray and CT or stool cultures for C. diff
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Antibiotic choice in patients with standard risk neutropenic sepsis

A

1) IV piperacillin/tazobactam 4.5g qds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Antibiotic choice in patients with high risk neutropenic sepsis

A

1) IV piperacillin/tazobactam 4.5g qds + IV gentamicin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Side effects of Tazocin

A
  • GI upset
  • Rash, pruritis
  • Phlebitis
  • Insomnia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Side effects of Gentamicin

A
  • Neurotoxicity (vertigo, gait instability)
  • Ototoxicity
  • Nephrotoxicity
  • Oedema
  • Rash, pruritis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What does dose regime of Tazocin depend on

A

Renal function - creatinine clearance determines if Tazocin is given bd, td or qds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Antibiotic management of a patient with neutropenic sepsis with previous MRSA or presumed central line infection

A

1) IV Tazocin + Vancomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Antibiotic management of a patient with neutropenic sepsis with suspected atypical pneumonia

A

1) IV Tazocin + Clarithromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Side effects of Vancomycin

A
  • Anaphylactic reaction
  • ‘Red man’ syndrome
  • Back pain
  • Bradycardia
  • Chest pain
  • Dyspnoea
  • Hearing loss
  • Hypotension
  • Muscle pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Side effects of clarithromycin

A
  • Decreased appetite
  • GI upset
  • Dizziness
  • Headache
  • Insomnia
  • Pancreatitis
  • Skin reactions
  • Vasodilation
  • Vision disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What would you recommend in regards to chemotherapy treatment in a patient recovering from neutropenic sepsis?

A
  • Reduce dose of chemotherapy

OR

  • Delay chemotherapy cycle by a week
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Clinical features of malignant spinal cord compression

A
  • Pain (most commonly in the back, exaggerated by coughing and straining, and in a radicular pattern)
  • Weakness
  • Bowel problems
  • Altered sensation
  • Urinary incontinence
  • Faecal incontinence
  • Bilateral sciatica
  • Saddle anaesthesia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Radicular pain in a patient with previous/current malignancy is ??? until proven otherwise

A

malignant spinal cord compression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What is the 1st line investigation in a patient with ?malignant spinal cord compression

A

URGENT MRI of the WHOLE spine (within 24 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Management options for a patient with malignant spinal cord compression

A

1) 16mg PO dexamethasone (as a ‘holding measure’) followed by 8mg bd dexamethasone + PPI cover (given in the daytime)
2) Radiotherapy (20Gy in 5 fractions) to the affected area and 1-2 vertebrae above and below

OR

Surgery (fixation of the affected vertebrae) (1st line in indicated patients)

Or

OR

Chemotherapy (for sensitive tumours)

OR

Hormone treatment (in metastatic prostate cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Side effects of lumbar spine radiotherapy

A
  • Skin reaction
  • Fatigue
  • Cystitis
  • Diarrhoea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Indications for surgery in patients with malignant spinal cord compression

A
  • Single vertebral region of involvement
  • No evidence of widespread metastasis
  • Radio-resistant primary tumour (e.g. renal, sarcoma)
  • Previous radiotherapy to a affected site)
  • Unknown primary (allows us to get tissue for histology)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Causes of SVC obstruction

A
  • Bronchus cancer
  • Lung cancer (SCLC)
  • Lymphoma
  • Other malignancy
  • Aneurysms
  • Goitre
  • Fibrosis
  • Infection
  • Central line in situ
  • Thrombosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Clinical features of SVC obstruction

A
  • Swelling of face, neck, one/both arms
  • Distended veins
  • Shortness of breath
  • Lethargy
  • Headache
  • Nasal congestion
  • Epistaxis
  • Dizziness
  • Syncope
    Symptoms are often worse on bending forward or lying down
  • Neck veins don’t collapse on compression
  • Visible veins
  • Raised JVP
  • Arm oedema
  • Plethora
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Investigations to consider in a patient with SVC obstruction

A

1) CXR (looking for a mass)
2) CT chest with contrast (provides 3D information about the cause - contrast will accumulate in the area before the obstruction)
3) Venogram
4) Routine bloods and coagulation screen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Management of a patient with malignant SVC obstruction

A

Dexamethasone is often given first line (although there is limited evidence for this)

1) Radiological stenting
2) Chemotherapy (in SCLC, lymphoma, teratoma)
OR
Radiotherapy (in other malignant causes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Define malignant hypercalcemia

A

Corrected serum calcium >2.65 mmol/L on two occasions in patients with malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

3 most common causes of malignant hypercalcemia

A
  • Lung cancer
  • Breast cancer
  • Multiple myeloma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Differentials for malignant hypercalcemia

A
  • Brain/bony metastasis
  • Delirium
  • Paraneoplastic syndrome
  • Electrolyte imbalances
  • Infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Clinical features of malignant hypercalcemia

A

May be asymptomatic (particularly in mild cases)

  • Bone pain, pathological fractures
  • Delirium, drowsiness, coma
  • Fatigue
  • Muscle weakness
  • Impaired concentration and memory
  • Depression
  • GI upset
  • Polyuria, polydipsia and dehydration
  • Renal colic, renal stones, renal impairment
  • Hypertension
  • Shortened QT on ECG
  • Pruritus
  • Eye infections, corneal calcifications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Investigations to consider in a patient with ?malignant hypercalcemia

A
  • General infection screen e.g. MSU
  • Routine bloods including calcium and PTH
  • CT head (rule out brain metastasis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Management of a patient with malignant hypercalcemia

A

1) Adequate rehydration to correct dehydration
- Oral rehydration if appropriate
- 3L of 0.9% NaCl over 24 hours

2) IV zolendronate 4mg over 15 mins in 100ml 0.9% NaCl (if eGFR >30)
OR
Pamidronate (if eGFR <30)

3) Review medications affecting renal function (e.g. NSAIDs, diuretics, ACE inhibitors)
4) Check U&Es in 3-4 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Management of a patient with neutropenic sepsis with a penicillin allergy

A

1) IV Vancomycin + Metronidazole + PO Ciprofloxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Side effects of metronidazole

A
  • Dry mouth
  • Myalgia
  • GI upset
  • Metallic taste
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Side effects of ciprofloxacin

A
  • Tendon damage
  • Arthralgia, myalgia
  • GI upset
  • Dizziness
  • Dyspnoea
  • Fever
  • Headache
  • QT prolongation
  • Skin reactions
  • Sleep disorders
  • Altered taste
  • Tinnitus
  • Vision disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Oral antibiotic stepdown in patients with neutropenic sepsis

A

Co-amoxiclav + ciprofloxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Indications for GCS-F in patients with neutropenic sepsis

A
  • Profound neutropenia (<0.1)
  • Prolonged neutropenia (> 10 days)
  • Pneumonia
  • Hypotension
  • Multi-organ dysfunction
  • Uncontrolled primary disease
  • Invasive fungal infection
  • Age >65
  • Hospital inpatient at time of developing fever
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Most common malignant causes of spinal cord compression

A
  • Breast
  • Lung
  • Prostate
  • Multiple myeloma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What is the scoring system used to consider surgery in patients with malignant spinal cord compression, and what factors does it take into account?

A

Tokuhasi score:

  • Patient’s general condition
  • Number of extra-spinal bone metastasis
  • Number of spinal bone metastasis
  • Metastasis in major organs
  • Primary site of cancer
  • Neurological deficit
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

What blood tests should you request to monitor a patient on bisphosphonates

A
  • Renal function
  • Calcium
  • Phosphate
  • Potassium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Side effects of bisphosphonates

A
  • GI upset
  • Flu-like symptoms
  • Osteonecrosis of the jaw
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Mechanism of action of Tamoxifen

A

Oestrogen receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Route of administration of Tamoxifen

A

Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Indications for Tamoxifen

A
  • ER+ breast cancer (as adjuvant or neb-adjuvant therapy) post-surgery/radiotherapy in pre- or peri-menopausal women
  • Breast cancer patients for 5 years after tumour removal
  • Primary prevention of breast cancer (in women >30 with moderate/high risk)
  • Gynaecomastia in males
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Contraindications for tamoxifen

A
  • Family/personal history of idiopathic VTE
  • Pregnancy
  • Concurrent anastrozole therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Side effects of tamoxifen

A

MOST IMPORTANT:

1) endometrial changes (hyperplasia, polyps, cancer, uterine sarcoma)
2) Increased risk of thromboembolism

  • Alopecia
  • Anaemia
  • Cataracts
  • Cerebral ischaemia
  • Fatigue
  • Fluid retention
  • Headache
  • Hot flushes
  • Nausea
  • Retinopathy

Tamoxifen DOES NOT affect bone mineral density

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Route of administration of aromatase inhibitors

A

Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Indications for letrozole

A
  • Adjuvant treatment of ER+ invasive early breast cancer in post-menopausal women
  • 1st line treatment in ER/PR+ or ER/PR status unknown locally advanced or metastatic breast cancer in post-menopausal women
  • Extended adjuvant therapy of early breast cancer in post-menopausal women who have received 5 years of adjuvant tamoxifen
  • Treatment of advanced breast cancer in post-menopausal women where other anti-oestrogen therapy has failed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Indications for exemestane

A
  • Adjuvant treatment of ER+ early breast cancer in post-menopausal women following 2-3 years of tamoxifen
  • Advanced breast cancer in post-menopausal women where anti-oestrogen therapy has failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Indications for anastrozole

A
  • Adjuvant treatment of ER+ early invasive breast cancer in post-menopausal women
  • Adjuvant treatment of ER+ early breast cancer in post-menopausal women following 2-3 years of tamoxifen
  • Advanced breast cancer in post-menopausal women which is ER+ or responsive to Tamoxifen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Contra-indications for aromatase inhibitors

A
  • Pre-menopausal women

- Pregnancy and breast feeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Side effects of aromatase inhibitors

A

MOST IMPORTANT:
1) Decreased bone mineral density/osteoporosis

  • Alopecia
  • Arthralgia
  • Hot flushes
  • Vaginal dryness
  • Oedema
  • Bone pain
  • Headache
  • GI upset
  • Carpal tunnel syndrome
  • Insomnia
  • Leucopenia
  • Thrombocytopenia
  • Skin reactions
85
Q

Monitoring required during aromatase inhibitor treatment

A
  • Bone mineral density
86
Q

Mechanism of action of Goserelin

A

GnRH receptor antagonist

87
Q

Route of administration of Goserelin

A

SC injection into anterior abdominal wall

88
Q

Indications for Goserelin

A
  • Locally advanced prostate cancer (as an alternative to surgery)
  • Adjuvant/neoadjuvant treatment to radiotherapy/radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer
  • Metastatic prostate cancer
  • Advanced breast cancer
  • ER+ early breast cancer
89
Q

Contra-indications for Goserelin

A
  • Undiagnosed vaginal bleeding

- Use for >6 months in endometriosis

90
Q

Side effects of Goserelin

A
  • Alopecia
  • Pain
  • Breast abnormalities
  • Altered mood, depression
  • Impaired glucose tolerance
  • Gynaecomastia
  • Headache
  • Heart failure
  • Hot flushes
  • Hyperhidrosis
  • MI
  • Neoplasm complications
  • Parasthesia
  • Sexual dysfunction
  • Skin reactions
  • Spinal cord compression
  • Vulvovaginal disorders
  • Weight gain
91
Q

Monitoring required on Goserelin

A
  • Men at risk of ‘tumour flare’ (temporary worsening of disease) should be closely monitored during first month of treatment for prostate cancer
  • Monitor for QT-prolongation and ventricular arrhythmia (in patients on QT-prolonging agents)
92
Q

Drug interactions of Goserelin

A

Goserelin interacts with QT-prolonging agents

93
Q

Mechanism of action of Herceptin

A

Monoclonal antibody which down-regulates HER2

94
Q

Route of administration of Herceptin

A

SC injection or IV infusion

95
Q

Indications for Herceptin

A
  • Early HER2+ breast cancer
  • Metastatic HER2+ breast cancer in patients who have not received chemotherapy and where Anthracyclines treatment is inappropriate (given in combination with paclitaxel or docetexal)
  • Monotherapy for metastatic breast cancer patients who have previously received at least 2 chemotherapy agents
  • Metastatic HER2+, ER/PR+ breast cancer in post-menopausal women not previously treated with Herceptin
  • Metastatic HER2+ gastric cancer
96
Q

Contra-indications for Herceptin

A
  • Severe dyspnoea at rest

- Pregnancy, breast-feeding

97
Q

Side effects of Herceptin

A

MOST IMPORTANT:
1) Decreased ejection fraction and congestive heart failure

  • Headache
  • GI upset
  • Insomnia
  • Cough
  • Rash
  • Cardiac disorders
  • Infection (including neutropenic sepsis)
  • Pancytopenia
  • Fatigue, malaise, pain
  • Tremor
  • Dizziness
  • Parasthesia
  • Altered sense of taste
  • Hot flushes
  • Respiratory symptoms
  • Swollen face
  • Alopecia
  • Nail disorders
  • Hand-foot syndrome
  • Peripheral oedema
98
Q

Monitoring required when on Herceptin

A

Regular echocardiograms to assess ejection fraction

99
Q

Mechanism of action of Imatinib

A

Tyrosine kinase inhibitor - inhibits BCR-ABL in the Philadelphia chromosome and c-Kit

100
Q

Route of administration of Imatinib

A

Orally with food

101
Q

Indications for Imatinib

A
  • Philadelphia+ CML
  • Philadelphia+ ALL
  • C-KIT+ GIST
102
Q

Side effects of Imatinib

A

MOST IMPORTANT:

1) Hepatotoxicity
2) Cardiac toxicity

  • Pancytopenia
  • Fluid retention
  • GI upset
  • Photosensitivity
  • Alopecia
  • Myalgia, arthralgia
  • Blurred vision
  • Taste alteration
  • Skin changes
103
Q

Monitoring required when on Imatinib

A
  • FBC
  • LFTs
  • Monitor for GI haemorrhage
  • Monitor for fluid retention
  • Monitor for growth retardation (in children)
104
Q

Drug interactions with Imatinib

A
  • CYPA34 inhibitors (erythromycin) and inducers (carbamazepine, St JOhn’s wort)
  • Warfarin
105
Q

Mechanism of action of Capecitabine

A

Anti-metabolite - converted into fluorouracil in the tumour to inhibit DNA synthesis and slow tumour growth

106
Q

Route of administration of Capecitabine

A

Orally after a meal, bi-daily

Given for 14 days followed by a 7 day interval (course of 6 months)

107
Q

Indications for Capecitabine

A
  • Monotherapy is first line treatment of advanced colorectal cancer
  • Adjuvant therapy of patients with stage III colon cancer
  • Advanced gastric cancer
  • In combination with Docetexal in locally advanced or metastatic breast cancer
  • Monotherapy in advanced breast cancer after failure or taxmen and anthracyclines chemotherapy
108
Q

Contra-indications for Capecitabine

A
  • Dihydropyrimidine dehydrogenase deficiency
  • Severe liver dysfunction
  • Severe renal impairment
  • Thrombocytopenia
  • Neutropenia
  • Pregnancy/breast feeding
109
Q

Side effects of Capecitabine

A
  • GI upset and appetite suppression
  • Eye irritation
  • Fever
  • Alopecia
  • Stomatitis
  • Myelosuppression
  • Headache
  • Fatigue
  • Shortness of breath
  • Hand-foot syndrome
  • Weakness
  • Dermatitis
  • Pain
  • Peripheral oedema
110
Q

Monitoring required when on Capecitabine

A
  • Serum calcium
  • Monitoring for eye disorders
  • Monitoring for severe skin reactions e.g. Stevens-Johnson syndrome and toxic epidermal necrosis - discontinue permanently if these occur
111
Q

Mechanism of action of Rituximab

A

Anti-lymphocytic monoclonal antibody - causes apoptosis of B lymphocytes

112
Q

Route of administration of Rituximab

A

IV (or SC for non-Hodgkin’s lymphoma)

113
Q

Indications for Rituximab

A
  • Non-Hodgkin’s lymphoma
  • CLL
  • Autoimmune disease e.g. RA, SLE
114
Q

Contra-indications for Rituximab

A
  • Severe infection

- Severe heart failure, severe uncontrolled heart disease (when used for autoimmune disease)

115
Q

Side effects of Rituximab

A

MOST IMPORTANT:

1) Reactivation of Hepatitis B and TB infection
2) Induced serum sickness (triad of arthralgia, fever and rash)
3) Cytokine-releasing syndrome

Transient hypotension occurs frequently during infusion.

  • Angioedema
  • Anxiety
  • GI upset
  • Arrhythmia
  • Bone marrow disorders
  • Bursitis
  • Cancer pain
  • Cardiac disorders
  • Chest pain
  • Infection
  • Dizziness
  • Dysphagia, throat pain
  • Ear pain
  • Electrolyte imbalance
  • Hypercholesterolaemia
  • Hyperglycaemia
  • Hyperhidrosis
  • Insomnia
  • Lacrimation disorders
  • Malaise
  • Migraine
  • Multi-organ failure
  • Myalgia
  • Increased muscle tone
  • Nerve disorders
  • Oedema
  • Oral disorders
  • OA
  • Respiratory disorders
  • Abnormal sensation
  • Skin reactions
  • Tinnitus
116
Q

Screening required before starting Rituximab

A

Hepatitis B and TB screen

117
Q

Management steps for pain

A

1) Mild pain
- Paracetamol 1g qds
OR
- NSAID
(Reduce dose of paracetamol in poor nutritional status, low body weight, hepatic impairment, chronic alcohol abuse)

2) Mild-moderate pain
- ADD a weak opioid (codeine or dihydrocodeine 30-60mg qds)
OR
- Switch to a combined paracetamol codeine preparation (co-codamol 30/500, 2 tablets qds)
(Consider prescribing a laxative or anti-emetic)

3) Moderate-severe pain
- Switch from a weak to a strong opioid (24mg oral morphine in 24 hours)

118
Q

Adjuvant therapies available for pain management in palliative care

A
  • NSAID (bone pain, liver pain, soft tissue infiltration inflammatory pain)
  • Anti-depressants/anti-convulsants (nerve pain) - should be started at a low dose and titrated slowly
  • Dexamethasone (raised ICP, neuropathic or liver capsule pain)
  • TENS
  • Nerve block
  • Radiotherapy
  • Surgery
  • Bisphosphonates
  • Ketamine
  • Smooth/skeletal muscle relaxants
119
Q

NSAID side effects

A
  • GI ulcers/bleeding
  • Renal impairment
  • Fluid retention
  • Adverse cardiac events
120
Q

Amitryptilline side effects

A
  • Confusion
  • Hypotension
  • Dry mouth
  • Use with caution in CVD or risk of seizures
121
Q

Gabapentin side effects

A
  • Sedation
  • Tremor
  • Confusion
  • Use with caution in renal impairment
122
Q

Dexamethasone side effects

A
  • Insomnia
  • GI ulcer
  • Hyperglycaemia
  • Fluid retention
  • Infection e.g. candida
  • Myopathy
123
Q

Dose of breakthrough pain relief (compared to daily pain relief)

A

1/6th-1/10th (given as immediate release form)

124
Q

When should you seek specialist advice regarding pain control in palliative care patients

A
  • > 3 doses breakthrough pain relief given but patient still in pain
  • > 6 doses breakthrough pain relief in 24 hours
125
Q

Opioid management ladder

A

1) Mild-moderate pain:
- Codeine
- Dihydrocodeine
- Tramadol
- Buprenorphine patches

2) Moderate-severe pain:
- Morphine
- Diamorphine

  • Oxycodone
  • Fentanyl patch
  • Alfentanil
  • Fentanyl sublingual/buccal/intra-nasal
  • Hydromorphone
  • Methadone
126
Q

Analgesics to avoid in stage 4/5 CKD

A
  • Codeine
  • Dihydrocodeine
  • Morphine (titrate slowly and monitor in stages 1-3)
  • Diamorphine (titrate slowly and monitor in stages 1-3 and liver impairment)
  • Modified release Oxycodone
127
Q

Contra-indications/cautions for using Tramadol

A
  • Caution in stage 4/5 CKD
  • Caution in severe liver failure
  • CI with Monoamine oxidase inhibitors
  • CI in epilepsy
  • Avoid/use with caution in those on SSRIs or tricyclic antidepressants (risk of serotonin syndrome and lower seizure threshold)
128
Q

Drug of choice for high-dose SC breakthrough pain control injections

A

Diamorphine

129
Q

CIs for oxycodone

A
  • Severe liver impairment
  • Titrate slowly and minter in stages 1-3 CKD
  • CI in stage 4/5 CKD (for modified release form)
130
Q

Indications for fentanyl patch

A

Tolerant to opioids and chronic/stable pain

131
Q

Contra-indications/cautions for fentanyl patch

A
  • Monitor carefully in renal impairment
  • Reduce dose in liver impairment
  • Don’t initiate at end of life if oral route unavailable (can take too long to reach a steady state)
132
Q

Drug of choice for pain control in palliative care if eGFR <30 and a syringe driver is indicated

A

Alfentanil

133
Q

How would you convert a patient from immediate release morphine to modified release morphine?

A

Divide dose of 24 hour morphine by 2 and prescribe 12 hourly

134
Q

How would you convert a dose of an oral weak opioid to oral morphine?

A

Oral codeine/dihydrocodeine/tramadol –> oral morphine: divide dose by 10

135
Q

How would you convert a dose of an oral morphine to SC morphine?

A

Divide dose by 2

136
Q

How would you convert a dose of an oral morphine to SC Diamorphine?

A

Divide dose by 3

137
Q

How would you convert a dose of an oral morphine to oral oxycodone?

A

Divide dose by 2

138
Q

How would you convert a dose of an oral morphine to SC oxycodone?

A

Divide dose by 4

139
Q

How would you convert a dose of an oral oxycodone to SC oxycodone?

A

Divide by 2

140
Q

Precipitating factors for opioid toxicity

A
  • Rapid dose escalation
  • Renal impairment
  • Sepsis
  • Electrolyte abnormalities
  • Drug interactions
141
Q

Symptoms of opioid toxicity

A
  • Persistant sedation
  • Vivid dreams/hallucinations
  • Shadows at edge of visual fields
  • Delirium
  • Muscle twitching/myoclonus/jerking
  • Abnormal skin sensitivity to touch
142
Q

How to manage a patient with opioid toxicity

A
  • Reduce opioid dose by 1/3rd

- Ensure patient is well hydrated

143
Q

4 types of medication that can be prescribed using anticipatory care planning?

A

1) Opioids (for pain or breathlessness) e.g. morphine sulphate
2) Anxiolytic sedative (for anxiety, agitation or breathlessness) e.g. midazolam
3) Anti-secretory (for respiratory secretions) e.g. hyoscine butylbromide
4) Anti-emetic (for nausea and vomiting) e.g. levomepromazine

144
Q

Most common malignant causes of cachexia

A
  • Gastric
  • Pancreatice
  • NSCLC
  • SCLC
  • Prostate
  • Colon
  • NHL
  • Sarcoma
  • Acute non-lymphocytic leukaemia
  • Breast
145
Q

Reversible causes of anorexia

A
  • Pain
  • Breathlessness
  • Depression
  • Ascites
  • Nausea and vomiting
  • Constipation
  • Dysphagia
  • Heartburn
  • Gastritis
  • Anxiety
  • Medication
  • Oral problems
  • Odours
  • Delayed gastric emptying
  • Fatigue
146
Q

Symptoms of cachexia

A
  • Weight loss
  • Anorexia
  • Fatigue
  • Muscle wasting
  • Aesthesia
  • Anaemia
  • Oedema
147
Q

Pharmacological management of anorexia/cachexia

A
  • Corticosteroids (PO dexamethasone or prednisolone for 1 week then review) - may improve appetite and help nausea, energy levels and malaise. Effect is usually rapid but wears off after a few weeks.
  • Progestogens (megestrol acetate) - may stimulate appetite and weight gain. Onset of effect is slower but more prolonged than steroids.
148
Q

Side effects of progestogens

A
  • Nausea
  • Fluid retention
  • Increased risk of thromboembolism
149
Q

Pharmacological management of breathlessness in palliative care

A

1) Opioids (morphine)
2) Dexamethasone 8-16mg/daily (indicated in lymphangitis or tumour-associated airway obstruction)
3) Benzodiazepines
4) Oxygen
5) Nebulised saline

150
Q

Define delirium

A

Disturbed consciousness and inattention with cognitive impairment of acute onset and fluctuating course as a consequence of disease or treatment.

151
Q

Causes of delirium

A
  • Drugs e.g. opioids, anti-cholinergics, corticosteroids, benzodiazepines, antidepressants, sedatives
  • Drug withdrawal e.g. alcohol, sedatives, antidepressants, nicotine
  • Dehydration
  • Constipation
  • Urinary retention
  • Uncontrolled pain
  • Liver or renal impairment
  • Electrolyte imbalance
  • Infection
  • Hypoxia
  • Cerebral tumour
  • Cerebrovascular disease
152
Q

Pharmacological management of delirium in palliative care patients

A

1) Haloperidol PO or SC

2) Benzodiazepines

153
Q

Risk factors for depression in palliative care

A
  • Personal/family history of depression
  • Concurrent life stresses
  • Multiple losses
  • Unfulfilled life aspirations
  • Absence of social support
  • History of substance misuse/abuse
  • Oropharyngeal, pancreatic, breast and lung cancers
154
Q

Pharmacological management of depression in palliative care patients

A

1) SSRIs
2) Mirtazapine (well tolerated in elderly patients and heart failure)
3) Amitryptilline

155
Q

Side effects of SSRIs

A
  • GI upset
  • Risk of GI bleeding
  • Insomnia
  • Sweating
  • Impaired sexual function
  • Vivid dreams
  • Agitation
  • Hyponatremia
  • Risk of serotonin syndrome
156
Q

Investigations to consider in a palliative patient with nausea and vomiting

A
  • U&Es
  • LFTs
  • Calcium
  • Blood glucose
157
Q

Non-pharmacological management of a patient with nausea and vomiting

A
  • Regular mouth care
  • Regularising bowel habit
  • Regular, small, palatable meals
  • Avoid food preparation and cooking meals
  • Acupressure bands
  • Acupuncture
  • Psychological approaches
158
Q

Management of nausea/vomiting caused by chemical stimulation (e.g. drugs, malignancy, metabolic upset)

A

1) Dopamine receptor antagonist (metroclopramide, haloperidol, levomepromazine)

159
Q

Management of nausea/vomiting caused by motility disorders (e.g. gastric paresis)

A

1) Pro kinetic (metroclopramide)

160
Q

Management of nausea/vomiting caused by raised ICP or stimulation of the vestibular nerve

A

1) Cyclizine/hyoscine hydrobromide + dexamethasone
2) Levomepromazine
3) Prochloperazine

161
Q

Management of nausea/vomiting caused by cranial nerve irritation (oral, pharyngeal or oesophageal causes)

A

1) Cyclizine
2) Hyoscine hydrobromide
3) Levomepromazine

162
Q

Dopamine receptor antagonists used to treat nausea

A

Haloperidol

163
Q

5HT3 receptor antagonists used to treat nausea

A

-Setrons

164
Q

Anti-muscarinics used to treat nausea

A

Hyoscine hydrobromide

165
Q

Histamine 1 receptor antagonists used to treat nausea

A

Cyclizine

166
Q

5HT2 receptor antagonists used to treat nausea

A

Levomepromazine

167
Q

Factors leading to fatigue in cancer patients

A
  • Anaemia
  • Cancer treatment
  • Tumour bulk
  • Cytokine release
  • Depression and anxiety
  • Difficulty sleeping
  • Low degree of physical functioning
168
Q

Non-pharmacological management of fatigue in palliative care patients

A
  • Energy conservation/restoration plans
  • Exercise regimes
  • Stress reduction and increased psychological support
  • Sleep pattern advice
  • Recombinant EPO (may stimulate tumour progression in head and neck cancer)
169
Q

Pancreatic cancer tumour marker

A

Ca19-9

170
Q

Breast cancer tumour marker

A

Ca15-3

171
Q

Hepatic cancer tumour marker

A

AFP

172
Q

Colorectal cancer tumour marker

A

CEA

173
Q

Ovarian cancer tumour marker

A

Ca125

174
Q

Testicular cancer tumour markers

A

AFP

B-HCG

175
Q

Clinical features of a fibroadenoma

A
  • Young woman (18-25)

- Painless, mobile, firm breast lump

176
Q

Management of a fibroadenoma

A

None required usually

Surgical removal if >3cm or patient wants it removed

177
Q

Clinical features of duct ectasia

A
  • Women >50
  • Cheesy/white or thick green nipple discharge from single or multiple ducts
  • Slit like nipple retraction
  • Doughy palpable mass
178
Q

Risk factors for mastitis

A
  • Breast-feeding
  • Smoking
  • Diabetes
179
Q

Is lactational or non-lactational mastitis more serious?

A

Lactational - infection is usually more generalised and the patient is more systemically unwell so requires IV antibiotics

180
Q

Most common bacterial cause of breast abscess

A

S. Aureus

181
Q

Clinical features of mastitis

A
  • Usually affects one breast
  • Symptoms develop quickly
  • Red, swollen area/lump on breast
  • Hot and painful to touch
  • Area of hardness or tender fluctuating mass
  • Burning pain
  • Nipple discharge (white or blood-stained)
  • Malaise
182
Q

Indications for referral of a mastitis patient

A
  • Mastitis or breast inflammation which does not settle after 1 course of antibiotics
  • Abscess suspected
  • Breast inflammation in patient >35
183
Q

Management of lactational mastitis

A

1) Continue breast feeding
2) Antibiotics (if systemically unwell, nipple fissure present or symptoms don’t improve after 24-48 hours)
- 10-14 days Flucloxacillin 500mg QDS
OR
- Erythromycin 500mg BD

184
Q

Management of non-lactating mastitis

A

1) Co-amoxiclav 375mg TD
OR
2) Erythromycin 500mg WDS + Metronidazole 400mg TD

185
Q

Clinical features of intra-ductal papilloma

A
  • Clear or bloodstained nipple discharge originating from a single duct
186
Q

Clinical features of a breast cyst

A
  • Peri-menopausal women
  • Soft, fluctuant breast swelling
  • ‘Halo’ appearance on mammography
187
Q

Management of symptomatic breast cysts

A

Aspiration then re-examine the breast to ensure cyst has gone.

188
Q

Most common lung cancer in non-smokers

A

Adenocarcinoma

189
Q

Clinical features of lung cancer

A
  • Persistent cough
  • Haemoptysis
  • Dyspnoea
  • Chest pain
  • Weight loss and anorexia
  • Hoarseness
  • SVC syndrome
  • Fixed, monomorphic wheeze
  • Supraclavicular lymphadenopathy or persistent cervical lymphadenopathy
  • Finger clubbing
190
Q

Paraneoplastic features of SCLC

A
  • ADH - hyponatremia
  • ACTH - hypertension, hyperglycaemia, hypokalemia, alkalosis, muscle weakness
  • Lambert-Eaton syndrome
191
Q

Paraneoplastic features of squamous cell lung cancer

A
  • PTHrP - hypercalcemia
  • Finger clubbing
  • Hypertrophic pulmonary osteoarthropathy
  • Hyperthyroidism
192
Q

Paraneoplastic features of adenocarcinoma

A
  • Gynaecomastia

- Hypertrophic pulmonary osteoarthropathy

193
Q

Indications for an URGENT CXR in suspected lung cancer

A

Patients >40 with 2 or more of the following symptoms OR 1 symptom + smoking history:

  • Cough
  • Fatigue
  • Shortness of breath
  • Chest pain
  • Weight loss
  • Appetite loss

OR patients >40 with ANY of the following:

  • Persistent or recurrent chest infections
  • Finger clubbing
  • Supraclavicular lymphadenopathy or persistent cervical lymphadenopathy
  • Chest signs consistent with lung cancer
  • Thrombocytosis
194
Q

Investigations to consider in a patient with suspected lung cancer

A
  • CXR
  • CT
  • Bronchoscopy
  • PET scanning
  • FBC
195
Q

Indications for urgent referral for lung cancer work up

A
  • CXR findings that suggest lung cancer

- >40 with unexplained haemoptysis

196
Q

Management of SCLC

A

Chemotherapy + radiotherapy

197
Q

Contra-indications for surgery in NSCLC patients

A
  • Poor general health
  • Metastatic disease
  • FEV <1.5L
  • Malignant pleural effusion
  • Tumour near hilum
  • Vocal cord paralysis
  • SVC obstruction
198
Q

3 ‘types’ of colon cancer

A

1) Sporadic
2) HNPCC-associated
3) FAP-associated

199
Q

Mode of inheritance for HNPCC and FAP

A

Autosomal dominant

200
Q

Clinical features of colorectal cancer

A
  • Persistant changes in bowel habit
  • Rectal bleeding
  • Persistent abdominal discomfort
  • Tenesmus
  • Weakness or fatigue
  • Unexplained weight loss
201
Q

Indications for urgent referral for colorectal cancer work up

A
  • Patients >40 with unexplained weight loss and abdominal pain
  • Patients >50 with unexplained rectal bleeding
  • Patients >60 with iron deficiency anaemia OR change in bowel habit

Consider referral in:

  • Rectal or abdominal mass
  • Unexplained anal mass or anal ulceration
  • Patients <50 with rectal bleeding AND abdominal pain/change in bowel habit/weight loss/iron deficiency anaemia
202
Q

Screening programme for colorectal cancer

A

Faecal Immunochemical testing offered every 2 years to men and women 60-74 in England and 50-74 in Scotland

203
Q

Follow up for patients with a positive FOB test

A

Colonoscopy

204
Q

Indications for FOBT (outside normal screening criteria)

A
  • Patients >50 with unexplained abdominal pain OR weight loss
  • Patients <60 with changes in bowel habit or iron deficiency anaemia
  • Patients >60 with anaemia
205
Q

Risk factors for ovarian cancer

A
  • Family history - BRCA1/2 mutations

- Many ovulations e.g. early menarche, late menopause, nulliparity

206
Q

Clinical features of ovarian cancer

A
  • Age >60
  • Abdominal distention and bloating
  • Abdominal and pelvic pain
  • Urinary symptoms e.g. urgency
  • Early satiety
  • Diarrhoea
207
Q

Investigations to consider in a patient with suspected ovarian cancer

A

1) Ca125 (not to be used to screen asymptomatic women)
2) Urgent abdo/pelvis US (if Ca125 >35)
3) Diagnostic laparotomy

208
Q

Causes of an increased Ca125

A
  • Endometriosis
  • Menstruation
  • Benign ovarian cysts
209
Q

Management of ovarian cancer

A

Combination of surgery and platinum-based chemotherapy

Year 5 (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions